These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 23666487)

  • 1. Pharmacological approaches to restore mitochondrial function.
    Andreux PA; Houtkooper RH; Auwerx J
    Nat Rev Drug Discov; 2013 Jun; 12(6):465-83. PubMed ID: 23666487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial biogenesis: pharmacological approaches.
    Valero T
    Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted drug delivery to mammalian mitochondria in living cells.
    Weissig V
    Expert Opin Drug Deliv; 2005 Jan; 2(1):89-102. PubMed ID: 16296737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular machinery of mitochondrial fusion and fission: An opportunity for drug discovery?
    Zorzano A; Sebastián D; Segalés J; Palacín M
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):597-606. PubMed ID: 19736619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitophagy in neurodegeneration: an opportunity for therapy?
    Santos RX; Correia SC; Carvalho C; Cardoso S; Santos MS; Moreira PI
    Curr Drug Targets; 2011 Jun; 12(6):790-9. PubMed ID: 21269269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondria as a therapeutic target for common pathologies.
    Murphy MP; Hartley RC
    Nat Rev Drug Discov; 2018 Dec; 17(12):865-886. PubMed ID: 30393373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting drugs to mitochondria.
    Heller A; Brockhoff G; Goepferich A
    Eur J Pharm Biopharm; 2012 Sep; 82(1):1-18. PubMed ID: 22687572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
    Beal MF
    J Bioenerg Biomembr; 2004 Aug; 36(4):381-6. PubMed ID: 15377876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial energetics in the kidney.
    Bhargava P; Schnellmann RG
    Nat Rev Nephrol; 2017 Oct; 13(10):629-646. PubMed ID: 28804120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease.
    Esteves AR; Gozes I; Cardoso SM
    Biochim Biophys Acta; 2014 Jan; 1842(1):7-21. PubMed ID: 24120997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial Dysfunction in Parkinson's Disease: New Mechanistic Insights and Therapeutic Perspectives.
    Park JS; Davis RL; Sue CM
    Curr Neurol Neurosci Rep; 2018 Apr; 18(5):21. PubMed ID: 29616350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyhydroxylated fullerene derivative C(60)(OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+) -induced cellular model of Parkinson's disease.
    Cai X; Jia H; Liu Z; Hou B; Luo C; Feng Z; Li W; Liu J
    J Neurosci Res; 2008 Dec; 86(16):3622-34. PubMed ID: 18709653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic anti-Parkinsonism activity of high doses of B vitamins in a chronic cellular model.
    Jia H; Liu Z; Li X; Feng Z; Hao J; Li X; Shen W; Zhang H; Liu J
    Neurobiol Aging; 2010 Apr; 31(4):636-46. PubMed ID: 18639366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of pharmacological strategies for mitochondrial disorders.
    Kanabus M; Heales SJ; Rahman S
    Br J Pharmacol; 2014 Apr; 171(8):1798-817. PubMed ID: 24116962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor 1 (IGF-1) therapy: Mitochondrial dysfunction and diseases.
    Sádaba MC; Martín-Estal I; Puche JE; Castilla-Cortázar I
    Biochim Biophys Acta; 2016 Jul; 1862(7):1267-78. PubMed ID: 27020404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repairing Mitochondrial Dysfunction in Disease.
    Sorrentino V; Menzies KJ; Auwerx J
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():353-389. PubMed ID: 28961065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamin-related protein-1 as potential therapeutic target in various diseases.
    Singh S; Sharma S
    Inflammopharmacology; 2017 Aug; 25(4):383-392. PubMed ID: 28409390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of the Mitochondrial Unfolded Protein Response Induces Non-Apoptotic Dopaminergic Neurodegeneration in
    Martinez BA; Petersen DA; Gaeta AL; Stanley SP; Caldwell GA; Caldwell KA
    J Neurosci; 2017 Nov; 37(46):11085-11100. PubMed ID: 29030433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating multiple aspects of mitochondrial dynamics in neurons: age-related differences and dynamic changes in a chronic rotenone model.
    Arnold B; Cassady SJ; VanLaar VS; Berman SB
    Neurobiol Dis; 2011 Jan; 41(1):189-200. PubMed ID: 20850532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives of drug-based neuroprotection targeting mitochondria.
    Procaccio V; Bris C; Chao de la Barca JM; Oca F; Chevrollier A; Amati-Bonneau P; Bonneau D; Reynier P
    Rev Neurol (Paris); 2014 May; 170(5):390-400. PubMed ID: 24792485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.